SCHEMBL1767756

SCHEMBL1767756

Cc1ccc(-c2cc3ccccc3nc2N)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 1.00
KMT2A Q03164 3/20 1.00
NPC1 O15118 2/20 1.00
RAB9A P51151 2/20 1.00
KDM4E B2RXH2 5/20 0.56
ALDH1A1 P00352 5/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
MAPT P10636 1/20 0.56
HPGD P15428 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
GAA P10253 2/20 0.54
ATM Q13315 2/20 0.52
TLR8 Q9NR97 4/20 0.49
CYP1A1 P04798 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP1B1 Q16678 1/20 0.47
FGFR1 P11362 1/20 0.47
SRC P12931 1/20 0.47
PSMB5 P28074 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8574353 0.85 KMT2A (0.74) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL22509831 0.83 KMT2A (0.71) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL23496978 0.80 MEN1 (0.66) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL15249347 0.79 MEN1 (0.66) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL28281471 0.79 MEN1 (0.65) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL26551670 0.78 TDP1 (0.66) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL1767757 0.77 NPC1 (0.63) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL5318784 0.76 MEN1 (1.00) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL22509841 0.76 MEN1 (0.60) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL28281475 0.76 NPC1 (0.60) MEN1KMT2ANPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822485-B2 Amino heteroaryl compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2014-09-02 US disclosed
US-20130018064-A1 Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use AMGEN INC. (US) 2013-01-17 US disclosed
EP-2504330-A1 AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE Amgen Inc. (US) 2012-10-03 EP disclosed
WO-2011063272-A1 AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018064-A1 Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use BACE1, BACE2, APP MEN1 4504/4885KMT2A 1382/4885NPC1 1927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.